比较 COVID-19 患者中有和无维生素 D 不足者的心血管系统、临床状况和实验室结果。
Comparison of the cardiovascular system, clinical condition, and laboratory results in COVID-19 patients with and without vitamin D insufficiency.
机构信息
Student Research Committee, School of Medicine, Shahroud University of Medical Sciences, Shahroud, Iran.
Department of Epidemiology, School of Public Health, Shahroud University of Medical Sciences, Shahroud, Iran.
出版信息
BMC Infect Dis. 2022 May 7;22(1):441. doi: 10.1186/s12879-022-07438-8.
BACKGROUND
Serum vitamin D levels may have a protective role against severe coronavirus disease 2019 (COVID-19). Studies have shown that deficiency in vitamin D may be a significant risk factor for poor outcomes. This study aims to compare the outcome and clinical condition of patients diagnosed with COVID-19 infection considering serum vitamin D levels.
METHODS
In this cross-sectional study, 202 COVID-19 patients without known cardiovascular disease (reduced ejection fraction, uncontrolled arrhythmia, pericardial effusion, cardiac block, valvular disease, or hypertension) were included. Patients were divided into three groups of insufficient (< 30 ng/mL), normal (30 to 50 ng/mL), and high (> 50 ng/mL) serum vitamin D levels. Clinical outcome was defined as severe if invasive respiratory intervention and ICU admission was required.
RESULTS
The patients were divided into three groups based on their vitamin D level: 127 cases in the insufficient vitamin D group, 53 cases in the normal vitamin D group, and 22 cases in the high vitamin D group. The mean age of the population study was 56 years. Thirty-four patients had severe clinical outcomes. The distribution of this group was as follows: 21 patients in the insufficient vitamin D group (16.5%), eight patients in the normal vitamin D group (15.1%), and five patients in the high vitamin D group (22.7%); P = 0.74. No significant differences were found between the groups in terms of mortality rate (P = 0.46). Moreover, the mean of leukocytes (mean ± SD = 6873.5 ± 4236.2), ESR (mean ± SD = 38.42 ± 26.7), and CPK-MB (mean ± SD = 63 ± 140.7) were higher in the insufficient vitamin D group, but it was not statistically significant (P > 0.05).
CONCLUSION
The finding of the present study showed that vitamin D could not make a significant difference in cardiovascular systems, laboratory results, and severity of the disease in COVID-19 patients.
背景
血清维生素 D 水平可能对严重的 2019 年冠状病毒病（COVID-19）具有保护作用。研究表明，维生素 D 缺乏可能是预后不良的重要危险因素。本研究旨在比较考虑血清维生素 D 水平的 COVID-19 感染患者的结局和临床情况。
方法
在这项横断面研究中，纳入了 202 名无已知心血管疾病（射血分数降低、心律失常不受控制、心包积液、心脏传导阻滞、瓣膜疾病或高血压）的 COVID-19 患者。患者被分为三组，血清维生素 D 水平不足（<30ng/mL）、正常（30 至 50ng/mL）和高水平（>50ng/mL）。如果需要侵入性呼吸干预和 ICU 入院，则将临床结局定义为严重。
结果
根据维生素 D 水平将患者分为三组：维生素 D 不足组 127 例，维生素 D 正常组 53 例，维生素 D 高水平组 22 例。人群研究的平均年龄为 56 岁。34 例患者出现严重临床结局。该组的分布如下：维生素 D 不足组 21 例（16.5%），维生素 D 正常组 8 例（15.1%），维生素 D 高水平组 5 例（22.7%）；P=0.74。三组之间死亡率无显著差异（P=0.46）。此外，维生素 D 不足组的白细胞均值（均值±标准差=6873.5±4236.2）、红细胞沉降率（均值±标准差=38.42±26.7）和肌酸激酶同工酶-MB（均值±标准差=63±140.7）较高，但无统计学意义（P>0.05）。
结论
本研究发现，维生素 D 不能在 COVID-19 患者的心血管系统、实验室结果和疾病严重程度方面产生显著差异。
Zotero 插件